genedrive shares climb 8% on Thermo Fisher pharmacogenetic testing deal

genedrive PLC signed a collaboration agreement with Thermo Fisher Scientific to develop a high-throughput laboratory pharmacogenetic test. The news was welcomed by the market, with genedrive shares rising 8% to 1.4p. The update is strategically positive for the company but does not disclose financial terms or near-term revenue impact.

Analysis

genedrive PLC signed a collaboration agreement with Thermo Fisher Scientific to develop a high-throughput laboratory pharmacogenetic test. The news was welcomed by the market, with genedrive shares rising 8% to 1.4p. The update is strategically positive for the company but does not disclose financial terms or near-term revenue impact.